Td Asset Management Inc Blueprint Medicines Corp Transaction History

Td Asset Management Inc

  • $107 Billion
  • Q3 2024

A detailed history of Td Asset Management Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Td Asset Management Inc holds 266,500 shares of BPMC stock, worth $30.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
266,500
Previous 323,500 17.62%
Holding current value
$30.2 Million
Previous $34.9 Million 29.33%
% of portfolio
0.02%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
SELL
$84.1 - $120.5 $4.79 Million - $6.87 Million
-57,000 Reduced 17.62%
266,500 $24.6 Million
Q2 2024

Aug 02, 2024
SELL
$85.18 - $108.78 $5.11 Million - $6.52 Million
-59,970 Reduced 15.64%
323,500 $34.9 Million
Q1 2024

May 08, 2024
BUY
$73.17 - $99.79 $6.41 Million - $8.74 Million
87,554 Added 29.59%
383,470 $36.4 Million
Q4 2023

Feb 12, 2024
SELL
$43.96 - $92.84 $896,256 - $1.89 Million
-20,388 Reduced 6.45%
295,916 $27.3 Million
Q3 2023

Oct 27, 2023
BUY
$46.9 - $66.0 $5.85 Million - $8.24 Million
124,792 Added 65.16%
316,304 $15.9 Million
Q2 2023

Aug 09, 2023
BUY
$42.2 - $66.37 $1.02 Million - $1.6 Million
24,160 Added 14.44%
191,512 $12.1 Million
Q1 2023

May 10, 2023
BUY
$37.97 - $50.0 $919,937 - $1.21 Million
24,228 Added 16.93%
167,352 $7.53 Million
Q4 2022

Feb 06, 2023
BUY
$41.06 - $66.48 $665,172 - $1.08 Million
16,200 Added 12.76%
143,124 $6.27 Million
Q3 2022

Nov 07, 2022
BUY
$49.93 - $77.7 $1.54 Million - $2.4 Million
30,900 Added 32.18%
126,924 $8.36 Million
Q2 2022

Aug 04, 2022
SELL
$45.23 - $70.15 $226,149 - $350,750
-5,000 Reduced 4.95%
96,024 $4.85 Million
Q1 2022

May 10, 2022
SELL
$54.1 - $110.08 $263,899 - $536,970
-4,878 Reduced 4.61%
101,024 $6.45 Million
Q4 2021

Feb 10, 2022
BUY
$94.25 - $115.99 $2.18 Million - $2.69 Million
23,164 Added 28.0%
105,902 $11.3 Million
Q3 2021

Nov 09, 2021
BUY
$80.98 - $109.47 $510,174 - $689,661
6,300 Added 8.24%
82,738 $8.51 Million
Q2 2021

Aug 11, 2021
BUY
$82.78 - $101.0 $83,938 - $102,414
1,014 Added 1.34%
76,438 $6.72 Million
Q1 2021

May 14, 2021
BUY
$90.71 - $108.28 $844,963 - $1.01 Million
9,315 Added 14.09%
75,424 $7.33 Million
Q4 2020

Feb 16, 2021
BUY
$92.08 - $124.48 $562,977 - $761,070
6,114 Added 10.19%
66,109 $7.41 Million
Q3 2020

Nov 10, 2020
BUY
$66.45 - $92.7 $73,095 - $101,970
1,100 Added 1.87%
59,995 $5.56 Million
Q2 2020

Aug 13, 2020
BUY
$57.09 - $79.27 $131,307 - $182,321
2,300 Added 4.06%
58,895 $4.59 Million
Q1 2020

May 15, 2020
SELL
$48.11 - $82.22 $121,381 - $207,441
-2,523 Reduced 4.27%
56,595 $3.31 Million
Q4 2019

Feb 11, 2020
SELL
$66.73 - $82.59 $533,840 - $660,720
-8,000 Reduced 11.92%
59,118 $4.74 Million
Q3 2019

Nov 07, 2019
SELL
$72.9 - $101.41 $218,700 - $304,230
-3,000 Reduced 4.28%
67,118 $4.93 Million
Q2 2019

Aug 01, 2019
BUY
$73.54 - $97.8 $543,681 - $723,035
7,393 Added 11.79%
70,118 $6.61 Million
Q1 2019

May 08, 2019
SELL
$48.7 - $86.6 $14,610 - $25,980
-300 Reduced 0.48%
62,725 $5.02 Million
Q4 2018

Feb 01, 2019
BUY
$45.57 - $74.26 $68,355 - $111,390
1,500 Added 2.44%
63,025 $3.4 Million
Q3 2018

Nov 01, 2018
SELL
$58.91 - $78.32 $70,692 - $93,983
-1,200 Reduced 1.91%
61,525 $4.8 Million
Q2 2018

Jul 31, 2018
SELL
$60.96 - $101.18 $56,692 - $94,097
-930 Reduced 1.46%
62,725 $3.98 Million
Q1 2018

May 11, 2018
BUY
$73.28 - $102.95 $212,512 - $298,555
2,900 Added 4.77%
63,655 $5.84 Million
Q4 2017

Feb 02, 2018
BUY
$62.91 - $88.32 $579,715 - $813,868
9,215 Added 17.88%
60,755 $4.58 Million
Q3 2017

Nov 09, 2017
BUY
$42.37 - $69.67 $2.18 Million - $3.59 Million
51,540
51,540 $3.59 Million

Others Institutions Holding BPMC

# of Institutions
354
Shares Held
60.7M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.77B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email